WebOct 12, 2024 · 28 Sep 2024. Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab. The drug slowed decline on the primary endpoint, CDR-SB, by 27 percent over 18 months, and also nudged down decline on all secondary clinical endpoints. The incidence of the brain edema … WebApr 14, 2024 · The investigator-initiated clinical trial was a double-blind, active-controlled, Phase 2 trial that investigated the safety and efficacy of lysergide for treating 61 patients …
eFFECTOR Therapeutics Announces Positive Top-Line …
Web2 days ago · Top-line results from the trial are expected in the first half of 2024. The protocol of INVIGORATE-2 is substantially identical to that of the Phase 3 INVIGORATE clinical trial and a Phase 2 clinical trial, 1 both of which achieved the ocular itching … WebTHOUSAND OAKS, Calif., Dec. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, ... During clinical trials, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo. Depression was reported as serious in 0.1% (1/1308) of patients … theater company crossword clue
Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical …
WebAug 12, 2024 · Additional top-line results from other pediatric 20vPnC clinical trials are expected to read out in the second half of 2024, with discussions with other regulatory … WebJun 29, 2024 · The randomized, multi-center, double-blind SURE1 clinical trial enrolled 1,670 patients to measure efficacy, tolerability, and safety of oral sulopenem/probenecid for the … WebDUBLIN, June 28, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 RELEASE MSS1 trial ( NCT04657666) evaluating nabiximols oromucosal spray (JZP378, or Sativex ®, ex- U.S.) on clinical measures of spasticity in individuals with multiple sclerosis (MS). the god of high school 535